CymaBay Therapeutics (CBAY) Misses Q1 EPS by 20c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q1 EPS of ($0.29), $0.20 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• INVO Fertility (IVF) Tops Q2 EPS by 105c